FDA Approves Viracept, New Protease Inhibitor
ROCKVILLE, Md--The FDA has given Agouron Pharmaceuticals clearance to market its protease inhibitor Viracept (nelfinavir mesylate), under the accelerated approval process. Viracept was approved in both adult and pediatric formulations, for the treatment of HIV when antiretroviral therapy is warranted.
ROCKVILLE, Md--The FDA has given Agouron Pharmaceuticals clearance tomarket its protease inhibitor Viracept (nelfinavir mesylate), under theaccelerated approval process. Viracept was approved in both adult and pediatricformulations, for the treatment of HIV when antiretroviral therapy is warranted.
The indication is based on analyses of surrogate marker changes in patientswho received Viracept in combination with nucleoside analogues or alonefor up to 24 weeks. At present, there are no results from controlled trialsevaluating the effects of Viracept on clinical progression of HIV infection,such as survival or the incidence of opportunistic infections.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes
June 29th 2025Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.
